Management of ventricular arrhythmias: a trial-based approach.
Sudden cardiac death accounts for approximately 300,000 deaths annually in the U.S., and most of these are secondary to ventricular tachycardia (VT) and fibrillation in patients with coronary artery disease. Most patients with cardiac death die before reaching the hospital, which brought about a tremendous amount of research focused at identifying patients at high risk. Several trials were initiated to test the effectiveness of various therapeutic measures in these high-risk patients. A history of myocardial infarction, depressed left ventricular function and nonsustained VT have all been identified as independent risk factors for future arrhythmic death. Similarly, patients with a history of sustained VT or a history of sudden cardiac death are a high-risk group and should be aggressively evaluated and treated. The purpose of this article is to discuss risk stratification and primary prevention of sustained ventricular arrhythmias. We also review the recent secondary prevention trials and discuss the options available in the management of patients with sustained ventricular arrhythmias.
Welch
P J
PJ
Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, USA.
Page
R L
RL
Hamdan
M H
MH
D001145:Arrhythmias, Cardiac / Q000517:prevention & control* / Q000628:therapy; D002986:Clinical Trials as Topic; D006352:Heart Ventricles; D006801:Humans; D011322:Primary Prevention; D018570:Risk Assessment